Skip to main content
Top
Published in: European Journal of Pediatrics 1/2021

01-01-2021 | Obesity | Original Article

BMI in the lower and upper quartiles at diagnosis and at 1-year follow-up is significantly associated with higher risk of disease exacerbation in pediatric inflammatory bowel disease

Authors: Anat Yerushalmy-Feler, Tut Galai, Hadar Moran-Lev, Amir Ben-Tov, Margalit Dali-Levy, Yael Weintraub, Achiya Amir, Shlomi Cohen

Published in: European Journal of Pediatrics | Issue 1/2021

Login to get access

Abstract

Inflammatory bowel disease (IBD) has been associated with underweight and malnutrition, but obesity may also serve as a negative prognostic factor. This study aimed to present the longitudinal course of height, weight, and body mass index (BMI) of children from IBD diagnosis to 18 months of follow-up, and to describe the impact of BMI on the clinical course of the disease. One hundred and fifty-two children were identified, of whom 85 had Crohn’s disease (CD) and 67 had ulcerative colitis (UC). During a median (interquartile range) follow-up of 2.95 (1.73–4.5) years, weight and BMI Z-scores increased in the first 18 months since diagnosis in both the CD (P < 0.001) and UC (P < 0.028) groups. BMI in lower and upper quartiles at diagnosis was associated with higher risk of hospitalization (hazard ratio [HR] = 2.72, P = 0.021). In a multivariate analysis, BMI in the lower quartile at diagnosis and at 6, 12, and 18 months was associated with higher risk of disease exacerbation (HR = 2.36, 1.90, 1.98, and 2.43, respectively, P < 0.021), as was BMI in the upper quartile (HR = 2.59, 2.91, and 2.29, respectively, P < 0.013).
Conclusion: BMI in the lower and upper quartiles at diagnosis and during follow-up was associated with a more severe disease course in children with IBD.
What is Known:
• Inflammatory bowel disease (IBD) has been associated with underweight and malnutrition.
• The impacts of weight and body mass index (BMI) on the presentation and course of IBD have been mainly investigated in the adult population.
What is New:
• In the era of the obesity epidemic, this study identifies both low and high BMIs at diagnosis and at follow-up as a marker for poor outcome in pediatric IBD.
• The results support using BMI as a predictor of IBD course and prognosis.
Literature
1.
go back to reference Hildebrand H, Karlberg J, Kristiansson B (1994) Longitudinal growth in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 18:165–173CrossRef Hildebrand H, Karlberg J, Kristiansson B (1994) Longitudinal growth in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 18:165–173CrossRef
2.
go back to reference Dong J, Chen Y, Tang Y, Xu F, Yu C, Li Y, Pankaj P, Dai N (2015) Body mass index is associated with inflammatory bowel disease: a systematic review and metaanalysis. PLoS One 10:e0144872CrossRef Dong J, Chen Y, Tang Y, Xu F, Yu C, Li Y, Pankaj P, Dai N (2015) Body mass index is associated with inflammatory bowel disease: a systematic review and metaanalysis. PLoS One 10:e0144872CrossRef
3.
go back to reference Mamula P, Markowitz J, Baldassano R (2008) Growth impairment in pediatric inflammatory bowel disease. Pediatric Inflammatory Bowel Diseases. Springer, New York, pp 103–104CrossRef Mamula P, Markowitz J, Baldassano R (2008) Growth impairment in pediatric inflammatory bowel disease. Pediatric Inflammatory Bowel Diseases. Springer, New York, pp 103–104CrossRef
4.
go back to reference Kugathasan S, Nebel J, Skelton JA, Markowitz J, Keljo D, Rosh J, LeLeiko N, Mack D, Griffiths A, Bousvaros A, Evans J, Mezoff A, Moyer S, Oliva-Hemker M, Otley A, Pfefferkorn M, Crandall W, Wyllie R, Hyams J, Wisconsin Pediatric Inflammatory Bowel Disease Alliance, Pediatric Inflammatory Bowel Disease Collaborative Research Group (2007) Body mass index in children with newly diagnosed inflammatory bowel disease: observations from two multicenter North American inception cohorts. J Pediatr 151:523–527CrossRef Kugathasan S, Nebel J, Skelton JA, Markowitz J, Keljo D, Rosh J, LeLeiko N, Mack D, Griffiths A, Bousvaros A, Evans J, Mezoff A, Moyer S, Oliva-Hemker M, Otley A, Pfefferkorn M, Crandall W, Wyllie R, Hyams J, Wisconsin Pediatric Inflammatory Bowel Disease Alliance, Pediatric Inflammatory Bowel Disease Collaborative Research Group (2007) Body mass index in children with newly diagnosed inflammatory bowel disease: observations from two multicenter North American inception cohorts. J Pediatr 151:523–527CrossRef
5.
go back to reference Wiskin AE, Wootton SA, Hunt TM, Cornelius VR, Afzal NA, Jackson AA, Beattie RM (2011) Body composition in childhood inflammatory bowel disease. Clin Nutr 30:112–115CrossRef Wiskin AE, Wootton SA, Hunt TM, Cornelius VR, Afzal NA, Jackson AA, Beattie RM (2011) Body composition in childhood inflammatory bowel disease. Clin Nutr 30:112–115CrossRef
6.
go back to reference El Mouzan MI, Al Edreesi MH, Al-Hussaini AA et al (2016) Nutritional status of children with inflammatory bowel disease in Saudi Arabia. World J Gastroenterol 22:1854–1858CrossRef El Mouzan MI, Al Edreesi MH, Al-Hussaini AA et al (2016) Nutritional status of children with inflammatory bowel disease in Saudi Arabia. World J Gastroenterol 22:1854–1858CrossRef
7.
go back to reference Long MD, Crandall WV, Leibowitz IH, Duffy L, del Rosario F, Kim SC, Integlia MJ, Berman J, Grunow J, Colletti RB, Schoen BT, Patel AS, Baron H, Israel E, Russell G, Ali S, Herfarth HH, Martin C, Kappelman MD, ImproveCareNow Collaborative for Pediatric IBD (2011) Prevalence and epidemiology of overweight and obesity in children with inflammatory bowel disease. Inflamm Bowel Dis 17:2162–2168CrossRef Long MD, Crandall WV, Leibowitz IH, Duffy L, del Rosario F, Kim SC, Integlia MJ, Berman J, Grunow J, Colletti RB, Schoen BT, Patel AS, Baron H, Israel E, Russell G, Ali S, Herfarth HH, Martin C, Kappelman MD, ImproveCareNow Collaborative for Pediatric IBD (2011) Prevalence and epidemiology of overweight and obesity in children with inflammatory bowel disease. Inflamm Bowel Dis 17:2162–2168CrossRef
8.
go back to reference Blain A, Cattan S, Beaugerie L et al (2002) Crohn’s disease clinical course and severity in obese patients. Clin Nutr 21:51–57CrossRef Blain A, Cattan S, Beaugerie L et al (2002) Crohn’s disease clinical course and severity in obese patients. Clin Nutr 21:51–57CrossRef
9.
go back to reference Harper JW, Sinanan MN, Zisman TL (2013) Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease. Inflamm Bowel Dis 19:2118–2124CrossRef Harper JW, Sinanan MN, Zisman TL (2013) Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease. Inflamm Bowel Dis 19:2118–2124CrossRef
10.
go back to reference Hass DJ, Brensinger CM, Lewis JD et al (2006) The impact of increased body mass index on the clinical course of Crohn’s disease. Clin Gastroenterol Hepatol 4:482–488CrossRef Hass DJ, Brensinger CM, Lewis JD et al (2006) The impact of increased body mass index on the clinical course of Crohn’s disease. Clin Gastroenterol Hepatol 4:482–488CrossRef
11.
go back to reference Nic Suibhne T, Raftery TC, McMahon O, Walsh C, O'Morain C, O’Sullivan M (2013) High prevalence of overweight and obesity in adults with Crohn’s disease: associations with disease and lifestyle factors. J Crohn Colitis 7:e241–e248CrossRef Nic Suibhne T, Raftery TC, McMahon O, Walsh C, O'Morain C, O’Sullivan M (2013) High prevalence of overweight and obesity in adults with Crohn’s disease: associations with disease and lifestyle factors. J Crohn Colitis 7:e241–e248CrossRef
12.
go back to reference Flores A, Burstein E, Cipher DJ, Feagins LA (2015) Obesity in inflammatory bowel disease: a marker of less severe disease. Dig Dis Sci 60:2436–2445CrossRef Flores A, Burstein E, Cipher DJ, Feagins LA (2015) Obesity in inflammatory bowel disease: a marker of less severe disease. Dig Dis Sci 60:2436–2445CrossRef
13.
go back to reference Yerushalmy-Feler A, Ben-Tov A, Weintraub Y, Amir A, Galai T, Moran-Lev H, Cohen S (2018) High and low body mass index may predict severe disease course in children with inflammatory bowel disease. Scand J Gastroenterol 53:708–713CrossRef Yerushalmy-Feler A, Ben-Tov A, Weintraub Y, Amir A, Galai T, Moran-Lev H, Cohen S (2018) High and low body mass index may predict severe disease course in children with inflammatory bowel disease. Scand J Gastroenterol 53:708–713CrossRef
14.
go back to reference Levine A, Koletzko S, Turner D, Escher JC, Cucchiara S, de Ridder L, Kolho KL, Veres G, Russell RK, Paerregaard A, Buderus S, Greer ML, Dias JA, Veereman-Wauters G, Lionetti P, Sladek M, Martin de Carpi J, Staiano A, Ruemmele FM, Wilson DC, European Society of Pediatric Gastroenterology, Hepatology, and Nutrition (2014) ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 58:795–806PubMed Levine A, Koletzko S, Turner D, Escher JC, Cucchiara S, de Ridder L, Kolho KL, Veres G, Russell RK, Paerregaard A, Buderus S, Greer ML, Dias JA, Veereman-Wauters G, Lionetti P, Sladek M, Martin de Carpi J, Staiano A, Ruemmele FM, Wilson DC, European Society of Pediatric Gastroenterology, Hepatology, and Nutrition (2014) ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 58:795–806PubMed
15.
go back to reference Turner D, Griffiths AM, Walters TD, Seah T, Markowitz J, Pfefferkorn M, Keljo D, Otley A, LeLeiko NS, Mack D, Hyams J, Levine A (2010) Appraisal of the pediatric Crohn’s disease activity index on four prospectively collected datasets: recommended cutoff values and clinimetric properties. Am J Gastroenterol 105:2085–2092CrossRef Turner D, Griffiths AM, Walters TD, Seah T, Markowitz J, Pfefferkorn M, Keljo D, Otley A, LeLeiko NS, Mack D, Hyams J, Levine A (2010) Appraisal of the pediatric Crohn’s disease activity index on four prospectively collected datasets: recommended cutoff values and clinimetric properties. Am J Gastroenterol 105:2085–2092CrossRef
16.
go back to reference Turner D, Otley AR, Mack D, Hyams J, de Bruijne J, Uusoue K, Walters TD, Zachos M, Mamula P, Beaton DE, Steinhart AH, Griffiths AM (2007) Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 133:423–432CrossRef Turner D, Otley AR, Mack D, Hyams J, de Bruijne J, Uusoue K, Walters TD, Zachos M, Mamula P, Beaton DE, Steinhart AH, Griffiths AM (2007) Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 133:423–432CrossRef
17.
go back to reference Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, Fell J, Ruemmele FM, Walters T, Sherlock M, Dubinsky M, Hyams JS (2011) Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 17:1314–1321CrossRef Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, Fell J, Ruemmele FM, Walters T, Sherlock M, Dubinsky M, Hyams JS (2011) Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 17:1314–1321CrossRef
19.
go back to reference Heuschkel R, Salvestrini C, Beattie RM et al (2008) Guidelines for the management of growth failure in childhood inflammatory bowel disease. Inflamm Bowel Dis 14:839–849CrossRef Heuschkel R, Salvestrini C, Beattie RM et al (2008) Guidelines for the management of growth failure in childhood inflammatory bowel disease. Inflamm Bowel Dis 14:839–849CrossRef
20.
go back to reference Motil KJ, Grand RJ, Davis-Kraft L, Ferlic LL, Smith EO'B (1993) Growth failure in children with inflammatory bowel disease: a prospective study. Gastroenterology. 105:681–691CrossRef Motil KJ, Grand RJ, Davis-Kraft L, Ferlic LL, Smith EO'B (1993) Growth failure in children with inflammatory bowel disease: a prospective study. Gastroenterology. 105:681–691CrossRef
21.
go back to reference Diederen K, Krom H, Koole JCD, Benninga MA, Kindermann A (2018) Diet and anthropometrics of children with inflammatory bowel disease: a comparison with the general population. Inflamm Bowel Dis 24(8):1632–1640CrossRef Diederen K, Krom H, Koole JCD, Benninga MA, Kindermann A (2018) Diet and anthropometrics of children with inflammatory bowel disease: a comparison with the general population. Inflamm Bowel Dis 24(8):1632–1640CrossRef
22.
go back to reference Pfefferkorn M, Burke G, Griffiths A, Markowitz J, Rosh J, Mack D, Otley A, Kugathasan S, Evans J, Bousvaros A, Moyer MS, Wyllie R, Oliva-Hemker M, Carvalho R, Crandall W, Keljo D, Walters TD, LeLeiko N, Hyams J (2009) Growth abnormalities persist in newly diagnosed children with Crohn disease despite current treatment paradigms. J Pediatr Gastroenterol Nutr 48:168–174CrossRef Pfefferkorn M, Burke G, Griffiths A, Markowitz J, Rosh J, Mack D, Otley A, Kugathasan S, Evans J, Bousvaros A, Moyer MS, Wyllie R, Oliva-Hemker M, Carvalho R, Crandall W, Keljo D, Walters TD, LeLeiko N, Hyams J (2009) Growth abnormalities persist in newly diagnosed children with Crohn disease despite current treatment paradigms. J Pediatr Gastroenterol Nutr 48:168–174CrossRef
23.
go back to reference Ghersin I, Khateeb N, Katz LH, Daher S, Shamir R, Assa A (2019) Anthropometric measures in adolescents with inflammatory bowel disease: a population-based study. Inflamm Bowel Dis 25:1061–1065CrossRef Ghersin I, Khateeb N, Katz LH, Daher S, Shamir R, Assa A (2019) Anthropometric measures in adolescents with inflammatory bowel disease: a population-based study. Inflamm Bowel Dis 25:1061–1065CrossRef
24.
go back to reference Sawczenko A, Ballinger AB, Savage MO, Sanderson IR (2006) Clinical features affecting final adult height in patients with pediatric-onset Crohn’s disease. Pediatrics. 118:124–129CrossRef Sawczenko A, Ballinger AB, Savage MO, Sanderson IR (2006) Clinical features affecting final adult height in patients with pediatric-onset Crohn’s disease. Pediatrics. 118:124–129CrossRef
25.
go back to reference Herzog D, Fournier N, Buehr P et al (2014) Swiss IBD Cohort Study Group. Early onset Crohn’s disease is a risk factor for smaller final height. Eur J Gastroenterol Hepatol 26:1234–1239CrossRef Herzog D, Fournier N, Buehr P et al (2014) Swiss IBD Cohort Study Group. Early onset Crohn’s disease is a risk factor for smaller final height. Eur J Gastroenterol Hepatol 26:1234–1239CrossRef
26.
go back to reference Kuenzig ME, Benchimol EI, Lee L, Targownik LE, Singh H, Kaplan GG, Bernstein CN, Bitton A, Nguyen GC, Lee K, Cooke-Lauder J, Murthy SK (2019) The impact of inflammatory bowel disease in Canada 2018: direct costs and health services utilization. J Can Assoc Gastroenterol 2(Suppl 1):S17–S33CrossRef Kuenzig ME, Benchimol EI, Lee L, Targownik LE, Singh H, Kaplan GG, Bernstein CN, Bitton A, Nguyen GC, Lee K, Cooke-Lauder J, Murthy SK (2019) The impact of inflammatory bowel disease in Canada 2018: direct costs and health services utilization. J Can Assoc Gastroenterol 2(Suppl 1):S17–S33CrossRef
27.
go back to reference Bähler C, Vavricka SR, Schoepfer AM, Brüngger B, Reich O (2017) Trends in prevalence, mortality, health care utilization and health care costs of Swiss IBD patients: a claims data based study of the years 2010, 2012 and 2014. BMC Gastroenterol 17(1):138CrossRef Bähler C, Vavricka SR, Schoepfer AM, Brüngger B, Reich O (2017) Trends in prevalence, mortality, health care utilization and health care costs of Swiss IBD patients: a claims data based study of the years 2010, 2012 and 2014. BMC Gastroenterol 17(1):138CrossRef
28.
go back to reference Vester-Andersen MK, Vind I, Prosberg MV, Bengtsson BG, Blixt T, Munkholm P, Andersson M, Jess T, Bendtsen F (2014) Hospitalisation, surgical and medical recurrence rates in inflammatory bowel disease 2003-2011—a Danish population-based cohort study. J Crohns Colitis 8(12):1675–1683CrossRef Vester-Andersen MK, Vind I, Prosberg MV, Bengtsson BG, Blixt T, Munkholm P, Andersson M, Jess T, Bendtsen F (2014) Hospitalisation, surgical and medical recurrence rates in inflammatory bowel disease 2003-2011—a Danish population-based cohort study. J Crohns Colitis 8(12):1675–1683CrossRef
29.
go back to reference Jain A, Nguyen NH, Proudfoot JA, Martin CF, Sandborn WJ, Kappelman MD, Long MD, Singh S (2019) Impact of obesity on disease activity and Patient-Reported Outcomes Measurement Information System (PROMIS) in inflammatory bowel diseases. Am J Gastroenterol 114:630–639CrossRef Jain A, Nguyen NH, Proudfoot JA, Martin CF, Sandborn WJ, Kappelman MD, Long MD, Singh S (2019) Impact of obesity on disease activity and Patient-Reported Outcomes Measurement Information System (PROMIS) in inflammatory bowel diseases. Am J Gastroenterol 114:630–639CrossRef
30.
go back to reference Kurnool S, Nguyen NH, Proudfoot J, Dulai PS, Boland BS, Vande Casteele N, Evans E, Grunvald EL, Zarrinpar A, Sandborn WJ, Singh S (2018) High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitis. Aliment Pharmacol Ther 47:1472–1479CrossRef Kurnool S, Nguyen NH, Proudfoot J, Dulai PS, Boland BS, Vande Casteele N, Evans E, Grunvald EL, Zarrinpar A, Sandborn WJ, Singh S (2018) High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitis. Aliment Pharmacol Ther 47:1472–1479CrossRef
31.
go back to reference Singh S, Facciorusso A, Singh AG, Casteele NV, Zarrinpar A, Prokop LJ, Grunvald EL, Curtis JR, Sandborn WJ (2018) Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis. PLoS One 13:e0195123CrossRef Singh S, Facciorusso A, Singh AG, Casteele NV, Zarrinpar A, Prokop LJ, Grunvald EL, Curtis JR, Sandborn WJ (2018) Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis. PLoS One 13:e0195123CrossRef
32.
go back to reference Singh S, Proudfoot J, Xu R, Sandborn WJ (2018) Impact of obesity on short- and intermediate-term outcomes in inflammatory bowel diseases: pooled analysis of placebo arms of infliximab clinical trials. Inflamm Bowel Dis 24:2278–2284CrossRef Singh S, Proudfoot J, Xu R, Sandborn WJ (2018) Impact of obesity on short- and intermediate-term outcomes in inflammatory bowel diseases: pooled analysis of placebo arms of infliximab clinical trials. Inflamm Bowel Dis 24:2278–2284CrossRef
33.
go back to reference Bilski J, Mazur-Bialy A, Wojcik D et al (2019) Role of obesity, mesenteric adipose tissue, and adipokines in inflammatory bowel diseases. Biomolecules. 26(12):9 Bilski J, Mazur-Bialy A, Wojcik D et al (2019) Role of obesity, mesenteric adipose tissue, and adipokines in inflammatory bowel diseases. Biomolecules. 26(12):9
34.
go back to reference Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM (1995) Increased adipose tissue expression of tumor necrosis factor alpha in human obesity and insulin resistance. J Clin Invest 95:2409–2415CrossRef Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM (1995) Increased adipose tissue expression of tumor necrosis factor alpha in human obesity and insulin resistance. J Clin Invest 95:2409–2415CrossRef
35.
go back to reference Mohamed-Ali V, Goodrick S, Bulmer K et al (1999) Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. Am J Phys 277:E971–E975 Mohamed-Ali V, Goodrick S, Bulmer K et al (1999) Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. Am J Phys 277:E971–E975
36.
go back to reference Zulian A, Cancello R, Ruocco C, Gentilini D, di Blasio AM, Danelli P, Micheletto G, Cesana E, Invitti C (2013) Differences in visceral fat and fat bacterial colonization between ulcerative colitis and Crohn’s disease. An in vivo and in vitro study. PLoS One 8:e78495CrossRef Zulian A, Cancello R, Ruocco C, Gentilini D, di Blasio AM, Danelli P, Micheletto G, Cesana E, Invitti C (2013) Differences in visceral fat and fat bacterial colonization between ulcerative colitis and Crohn’s disease. An in vivo and in vitro study. PLoS One 8:e78495CrossRef
37.
go back to reference Erhayiem B, Dhingsa R, Hawkey CJ, Subramanian V (2011) Ratio of visceral to subcutaneous fat area is a biomarker of complicated Crohn’s disease. Clin Gastroenterol Hepatol 9:684–687CrossRef Erhayiem B, Dhingsa R, Hawkey CJ, Subramanian V (2011) Ratio of visceral to subcutaneous fat area is a biomarker of complicated Crohn’s disease. Clin Gastroenterol Hepatol 9:684–687CrossRef
Metadata
Title
BMI in the lower and upper quartiles at diagnosis and at 1-year follow-up is significantly associated with higher risk of disease exacerbation in pediatric inflammatory bowel disease
Authors
Anat Yerushalmy-Feler
Tut Galai
Hadar Moran-Lev
Amir Ben-Tov
Margalit Dali-Levy
Yael Weintraub
Achiya Amir
Shlomi Cohen
Publication date
01-01-2021
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Pediatrics / Issue 1/2021
Print ISSN: 0340-6199
Electronic ISSN: 1432-1076
DOI
https://doi.org/10.1007/s00431-020-03697-2

Other articles of this Issue 1/2021

European Journal of Pediatrics 1/2021 Go to the issue